Citations (38)
Keep up to date with the latest research on this topic with citation updates for this article.
Read on this site (1)
Camilla Porta, Hirad Houshmand, Massimiliano Povero, Lorenzo Pradelli, Filippo Monterosso, Matteo Pinciroli, Tabea Schuetze, Stefan Kirsch & Juan González del Castillo. (2023) Benefits of MR-proADM-guided decision-making in the emergency department: clinical and economic evaluation in Italy, Germany, Spain, and the UK. Journal of Medical Economics 26:1, pages 826-834.
Read now
Read now
Articles from other publishers (37)
Ester Forcano-Queralt, Cristina Lemes-Quintana & Domingo Orozco-Beltrán. (2023) Ambulatory management of low-risk febrile neutropenia in adult oncological patients. Systematic review. Supportive Care in Cancer 31:12.
Crossref
Crossref
Hirad Houshmand, Camilla Porta, Lorenzo Pradelli, Matteo Pinciroli & Giovanni Sotgiu. (2023) Cost-Impact Analysis of a Novel Diagnostic Test to Assess Community-Acquired Pneumonia Etiology in the Emergency Department Setting: A Multi-Country European Study. International Journal of Environmental Research and Public Health 20:5, pages 3853.
Crossref
Crossref
Nikki Rouw, Merel Boer, René J. Boosman, Michel M. Heuvel, David M. Burger, Joris E. Lieverse, Hieronymus J. Derijks, Geert W.J. Frederix & Rob Heine. (2022) The Pharmacoeconomic Benefits of Pemetrexed Dose Individualization in Patients With Lung Cancer. Clinical Pharmacology & Therapeutics 111:5, pages 1103-1110.
Crossref
Crossref
Inna P. Ganshina, Kristina A. Ivanova, Elena V. Lubennikova, Alexandr V. Arkhipov & Liudmila G. Zhukova. (2021) Improving early breast cancer treatment: the role of granulocyte colony-stimulating factor. Journal of Modern Oncology 22:4, pages 86-90.
Crossref
Crossref
Giuseppe Milone, Concetta Conticello, Salvatore Leotta, Maria Grazia Michieli, Massimo Martino, Anna Lia Di Marco, Andrea Spadaro, Alessandra Cupri, Annalisa Condorelli, Giulio Antonio Milone, Uros Markovic, Roberta Sciortino, Giovanni Schininà, Gaetano Moschetti, Loredana Villari & Riccardo Saccardi. (2020) Plerixafor on-demand in association with low-dose cyclophosphamide and G-CSF in the mobilization of patients with multiple myeloma: High effectiveness, low toxicity, and affordable cost. Leukemia Research Reports 14, pages 100227.
Crossref
Crossref
Giuseppe Toffoli, Federico Innocenti, Jerry Polesel, Elena De Mattia, Franca Sartor, Chiara Dalle Fratte, Fabrizio Ecca, Eva Dreussi, Elisa Palazzari, Michela Guardascione, Angela Buonadonna, Luisa Foltran, Marica Garziera, Alessia Bignucolo, Stefania Nobili, Enrico Mini, Adolfo Favaretto, Massimiliano Berretta, Mario D'Andrea, Antonino De Paoli, Rossana Roncato & Erika Cecchin. (2018)
The Genotype for
DPYD
Risk Variants in Patients With Colorectal Cancer and the Related Toxicity Management Costs in Clinical Practice
. Clinical Pharmacology & Therapeutics 105:4, pages 994-1002.
Crossref
Crossref
A. Carmona-Bayonas, P. Jimenez-Fonseca, E. M. de Castro, E. Mata, M. Biosca, A. Custodio, J. Espinosa, E. G. Vázquez, F. Henao & F. Ayala de la Peña. (2018) SEOM clinical practice guideline: management and prevention of febrile neutropenia in adults with solid tumors (2018). Clinical and Translational Oncology 21:1, pages 75-86.
Crossref
Crossref
Jennifer G Gaultney, Therese W Ng, Carin A Uyl-de Groot, Pieter Sonneveld, Erik H van Beers, Martin H van Vliet & William K Redekop. (2018) Potential therapeutic and economic value of risk-stratified treatment as initial treatment of multiple myeloma in Europe. Pharmacogenomics 19:3, pages 213-226.
Crossref
Crossref
José María Aguado, Juan Jesús Cruz, Juan Antonio Virizuela, Manuela Aguilar, Alberto Carmona, Javier Cassinello, Carlota Gudiol, Paula Jiménez Fonseca, Manuel Lizasoain, Francesc Marco, Isabel Ruiz, Maribel Ruiz, Miguel Salavert, David Vicente & Jordi Carratalà. (2017) Management of infection and febrile neutropenia in patients with solid cancer. Enfermedades infecciosas y microbiologia clinica (English ed.) 35:7, pages 451-460.
Crossref
Crossref
José María Aguado, Juan Jesús Cruz, Juan Antonio Virizuela, Manuela Aguilar, Alberto Carmona, Javier Cassinello, Carlota Gudiol, Paula Jiménez Fonseca, Manuel Lizasoain, Francesc Marco, Isabel Ruiz, Maribel Ruiz, Miguel Salavert, David Vicente & Jordi Carratalà. (2017) Manejo de la infección y la neutropenia febril en el paciente con cáncer sólido. Enfermedades Infecciosas y Microbiología Clínica 35:7, pages 451-460.
Crossref
Crossref
Eric Tai, Gery P. Guy, Angela Dunbar & Lisa C. Richardson. (2017) Cost of Cancer-Related Neutropenia or Fever Hospitalizations, United States, 2012. Journal of Oncology Practice 13:6, pages e552-e561.
Crossref
Crossref
Alexandre Vainchtock, Florence Boudevin, Gwendoline Chaize, Baptiste Jouaneton & Isabelle Durand-Zaleski. (2016) Estimation de la fréquence et des coûts associés aux neutropénies fébrile en France : analyse de la base de données des hôpitaux (PMSI) 2010/2011. Journal de gestion et d'économie médicales Vol. 34:1, pages 17-32.
Crossref
Crossref
Georgi Mihaylov, Zhasmina Mihaylova, Lubos Drgona, Andrea Cipkova, Jan Novak & Roumyana Petrova. (2016) Healthcare resource utilization and G‑CSF use in patients with solid tumors or hematological malignancies hospitalized for febrile neutropenia in Bulgaria, Czech Republic and Slovakia. memo - Magazine of European Medical Oncology 9:3, pages 144-152.
Crossref
Crossref
J. A. Virizuela, J. Carratalà, J. M. Aguado, D. Vicente, M. Salavert, M. Ruiz, I. Ruiz, F. Marco, M. Lizasoain, P. Jiménez-Fonseca, C. Gudiol, J. Cassinello, A. Carmona-Bayonas, M. Aguilar & J. J. Cruz. (2015) Management of infection and febrile neutropenia in patients with solid cancer. Clinical and Translational Oncology 18:6, pages 557-570.
Crossref
Crossref
EISEKI USAMI, MICHIO KIMURA, MINA IWAI, SHOYA TAKENAKA, HITOMI TERAMACHI & TOMOAKI YOSHIMURA. (2016) Chemotherapy continuity and incidence of febrile neutropenia with CHOP therapy in an outpatient setting. Molecular and Clinical Oncology 4:4, pages 591-596.
Crossref
Crossref
Xiao Jun Wang, Shaun Eric Lopez & Alexandre Chan. (2015) Economic burden of chemotherapy-induced febrile neutropenia in patients with lymphoma: A systematic review. Critical Reviews in Oncology/Hematology 94:2, pages 201-212.
Crossref
Crossref
D.E. Issa, H. Gelderblom, P.J. Lugtenburg, M.P. van Herk-Sukel, L.M.A. Houweling, M. De La Orden, M.E. van der Werf-Langenberg, J.W.R. Nortier & F.A. de Jong. (2015) Healthcare utilisation in patients with breast cancer or non-Hodgkin lymphoma who experienced febrile neutropenia in the Netherlands: a retrospective matched control study using the PHARMO database. European Journal of Cancer Care 24:2, pages 232-241.
Crossref
Crossref
Xiaoling Li, Yuqin Wang, Yan Wang, Jianhua Chen, Shengqi Wu, Chenping Hu, Yicheng Yang, Narayan Rajan, Manny Papadimitropoulos, Yi Chen, Tao Peng & Wendong Chen. (2015) Supportive Care Costs Associated with Second-Line Chemotherapy in Chinese Patients with Advanced Non-Squamous Non-Small Cell Lung Cancer: A Retrospective Cohort Study. Drugs - Real World Outcomes 2:1, pages 87-97.
Crossref
Crossref
Alberto Carmona-BayonasPaula Jiménez-FonsecaJuan Virizuela EchaburuMaite AntonioCarme FontMercè BioscaAvinash RamchandaniJerónimo MartínezJorge Hernando CuberoJavier EspinosaEva Martínez de CastroIsmael GhanemCarmen BeatoAna BlascoMarcelo GarridoYaiza BonillaRebeca MondéjarMaría Ángeles Arcusa LanzaIsabel Aragón ManriqueAránzazu ManzanoElena SevillanoEduardo CastañónMercé CardonaElena Gallardo MartínQuionia Pérez ArmillasFernando Sánchez LasherasFrancisco Ayala de la Peña. (2015) Prediction of Serious Complications in Patients With Seemingly Stable Febrile Neutropenia: Validation of the Clinical Index of Stable Febrile Neutropenia in a Prospective Cohort of Patients From the FINITE Study. Journal of Clinical Oncology 33:5, pages 465-471.
Crossref
Crossref
Sol Cortés de Miguel, Miguel Ángel Calleja-Hernández, Salomón Menjón-Beltrán & Inmaculada Vallejo-Rodríguez. (2014) Granulocyte colony-stimulating factors as prophylaxis against febrile neutropenia. Supportive Care in Cancer 23:2, pages 547-559.
Crossref
Crossref
Christian M. Kurbacher, Thomas Fietz, Ingo J. Diel, Matthias Egert, Hans-Jürgen Hurtz, Andreas Lück, Rudolf Weide, Christoph Salat, Thomas Wolff, Matthias Zaiss, Peter Klare, Christoph Losem, Thomas Illmer, Georg Weißenborn, Claus-Christoph Steffens, Matthias Schulze, Hans Tesch, Gülten Oskay-Oezcelik, Beate Teichmann, Johanna Harde & Robert Willy Scheuerlein. (2015) NADIR: A Non-Interventional Study on the Prophylaxis of Chemotherapy-Induced Neutropenia Using Lipegfilgrastim - First Interim Analysis. Oncology Research and Treatment 38:5, pages 221-229.
Crossref
Crossref
C. O'Brien, E. Fogarty, C. Walsh, O. Dempsey, M. Barry, M.J. Kennedy & L. McCullagh. (2015) The cost of the inpatient management of febrile neutropenia in cancer patients - a micro-costing study in the Irish healthcare setting. European Journal of Cancer Care 24:1, pages 125-132.
Crossref
Crossref
Xiao Jun Wang, Mabel Wong, Li Yang Hsu & Alexandre Chan. (2014) Costs associated with febrile neutropenia in solid tumor and lymphoma patients – an observational study in Singapore. BMC Health Services Research 14:1.
Crossref
Crossref
Csaba Fehér, Montserrat Rovira, Alex Soriano, Jordi Esteve, José Antonio Martínez, Francesc Marco, Enric Carreras, Carmen Martínez, Francesc Fernández-Avilés, María Suárez-Lledó & Josep Mensa. (2014) Effect of meropenem administration in extended infusion on the clinical outcome of febrile neutropenia: a retrospective observational study. Journal of Antimicrobial Chemotherapy 69:9, pages 2556-2562.
Crossref
Crossref
K. Krzemieniecki, P. Sevelda, F. Erdkamp, M. Smakal, M. Schwenkglenks, J. Puertas, A. Trojan, Z. Szabo, K. Bendall & J. Maenpaa. (2013) Neutropenia management and granulocyte colony-stimulating factor use in patients with solid tumours receiving myelotoxic chemotherapy—findings from clinical practice. Supportive Care in Cancer 22:3, pages 667-677.
Crossref
Crossref
Angela Ihbe-Heffinger, B. Paessens, K. Berger, M. Shlaen, R. Bernard, C. von Schilling & C. Peschel. (2013) The impact of chemotherapy-induced side effects on medical care usage and cost in German hospital care — an observational analysis on non-small-cell lung cancer patients. Supportive Care in Cancer 21:6, pages 1665-1675.
Crossref
Crossref
Julian F. Guest, Monica Panca, Erikas Sladkevicius, Nicholas Gough & Mark Linch. (2013) Cost Effectiveness of First-Line Treatment with Doxorubicin/Ifosfamide Compared to Trabectedin Monotherapy in the Management of Advanced Soft Tissue Sarcoma in Italy, Spain, and Sweden. Sarcoma 2013, pages 1-19.
Crossref
Crossref
Shannon L. Michels, Rich L. Barron, Matthew W. Reynolds, Karen Smoyer Tomic, Jingbo Yu & Gary H. Lyman. (2012) Costs Associated with Febrile Neutropenia in the US. PharmacoEconomics 30:9, pages 809-823.
Crossref
Crossref
Kay Leonard. (2012) A European survey relating to cancer therapy and neutropenic infections: Nurse and patient viewpoints. European Journal of Oncology Nursing 16:4, pages 380-386.
Crossref
Crossref
Markus Joerger, Stefanie Kraff, Alwin D. R. Huitema, Gary Feiss, Berta Moritz, Jan H. M. Schellens, Jos H. Beijnen & Ulrich Jaehde. (2012) Evaluation of a Pharmacology-Driven Dosing Algorithm of 3-Weekly Paclitaxel Using Therapeutic Drug Monitoring. Clinical Pharmacokinetics 51:9, pages 607-617.
Crossref
Crossref
Patricia M. LivingstonMelinda CraikeMonica Slavin. (2012) Clinical and Economic Burden of Emergency Department Presentations for Neutropenia Following Outpatient Chemotherapy for Cancer in Victoria, Australia. The Oncologist 17:7, pages 998-1004.
Crossref
Crossref
Ruth Pettengell, Hans E. Johnson, Pieternella J. Lugtenburg, Antonio Salar Silvestre, Ulrich Dührsen, Francesca G. Rossi, Matthias Schwenkglenks, Kate Bendall, Zsolt Szabo & Ulrich Jaeger. (2011) Impact of febrile neutropenia on R-CHOP chemotherapy delivery and hospitalizations among patients with diffuse large B-cell lymphoma. Supportive Care in Cancer 20:3, pages 647-652.
Crossref
Crossref
B.J. Paessens, C. von Schilling, K. Berger, M. Shlaen, C. Müller-Thomas, R. Bernard, C. Peschel & A. Ihbe-Heffinger. (2011) Health resource consumption and costs attributable to chemotherapy-induced toxicity in German routine hospital care in lymphoproliferative disorder and NSCLC patients. Annals of Oncology 22:10, pages 2310-2319.
Crossref
Crossref
Stephanie A. Gregory, Steve Abella & Tim Moore. (2011) Underreporting of neutropenic toxicity associated with current treatment regimens for selected hematologic malignancies. Community Oncology 8:7, pages 311-325.
Crossref
Crossref
M. Joerger, K. Matter-Walstra, M. Früh, U. Kühnel, T. Szucs, B. Pestalozzi & M. Schwenkglenks. (2011) Addition of cetuximab to first-line chemotherapy in patients with advanced non-small-cell lung cancer: a cost–utility analysis. Annals of Oncology 22:3, pages 567-574.
Crossref
Crossref
Angela Ihbe-Heffinger, Bernadette J. Paessens, Christoph von Schilling, Margarita Shlaen, Nina Gottschalk, Karin Berger, Rudolf Bernard, Marion Kiechle, Christian Peschel & Volker R. Jacobs. (2011) Management of Febrile Neutropenia – a German Prospective Hospital Cost Analysis in Lymphoproliferative Disorders, Non-Small Cell Lung Cancer, and Primary Breast Cancer. Onkologie 34:5, pages 241-246.
Crossref
Crossref
Yumi Asukai, Amparo Valladares, Carlos Camps, Eifiona Wood, Kaisa Taipale, Jorge Arellano, Alejo Cassinello, José Antonio Sacristán & Tatiana Dilla. (2010) Cost-effectiveness analysis of pemetrexed versus docetaxel in the second-line treatment of non-small cell lung cancer in Spain: results for the non-squamous histology population. BMC Cancer 10:1.
Crossref
Crossref